Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 11 (2011), Pages 1908-1931
http://dx.doi.org/10.1100/2011/924954
Review Article

Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

1Department of Internal Medicine, Università Politecnica delle Marche, 60121 Ancona, Italy
2Department of Hematology, Azienda Ospedaliera San Carlo, 85100 Potenza, Italy
3Department of Hematology, Università Politecnica delle Marche, 60121 Ancona, Italy

Received 9 August 2011; Accepted 5 September 2011

Academic Editor: Edward Benz

Copyright © 2011 Jacopo Olivieri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Lee, G. Vogelsang, and M. E. D. Flowers, “Chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 9, no. 4, pp. 215–233, 2003. View at Publisher · View at Google Scholar · View at PubMed
  2. A. H. Filipovich, D. Weisdorf, S. Pavletic et al., “National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report,” Biology of Blood and Marrow Transplantation, vol. 11, no. 12, pp. 945–956, 2005. View at Publisher · View at Google Scholar · View at PubMed
  3. S. J. Lee and M. E. Flowers, “Recognizing and managing chronic graft-versus-host disease,” Hematology, pp. 134–141, 2008. View at Google Scholar
  4. H. M. Shulman, D. Kleiner, S. J. Lee et al., “Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report,” Biology of Blood and Marrow Transplantation, vol. 12, no. 1, pp. 31–47, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. S. J. Lee, “Have we made progress in the management of chronic graft-vs-host disease?” Best Practice and Research, vol. 23, no. 4, pp. 529–535, 2010. View at Publisher · View at Google Scholar · View at PubMed
  6. S. Bhatia, L. Francisco, A. Carter et al., “Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor study,” Blood, vol. 110, no. 10, pp. 3784–3792, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. M. E. D. Flowers, Y. Inamoto, P. A. Carpenter et al., “Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria,” Blood, vol. 117, pp. 3214–3219, 2011. View at Google Scholar
  8. R. E. Billingham, “The biology of graft-versus-host reactions,” Harvey Lectures, vol. 62, pp. 21–78, 1966. View at Google Scholar
  9. J. L. M. Ferrara and J. H. Antin, “The pathophysiology of graft-vs.-host disease,” in Thomas' Hematopoietic Cell Transplantation, K. G. Blume, S. J. Forman, and F. R. Appelbaum, Eds., pp. 353–368, Blackwell Publishing, Malden, Mass, USA, 3rd edition, 2004. View at Google Scholar
  10. J. L. Ferrara, J. E. Levine, P. Reddy, and E. Holler, “Graft-versus-host disease,” The Lancet, vol. 373, no. 9674, pp. 1550–1561, 2009. View at Publisher · View at Google Scholar
  11. M. A. Schroeder and J. F. DiPersio, “Mouse models of graft-versus-host disease: advances and limitations,” Disease Models & Mechanisms, vol. 4, pp. 318–333, 2011. View at Google Scholar
  12. Y. W. Chu and R. E. Gress, “Murine models of chronic graft-versus-host disease: insights and unresolved issues,” Biology of Blood and Marrow Transplantation, vol. 14, no. 4, pp. 365–378, 2008. View at Publisher · View at Google Scholar · View at PubMed
  13. P. J. Martin, “Biology of chronic graft-versus-host disease: implications for a future therapeutic approach,” Keio Journal of Medicine, vol. 57, no. 4, pp. 177–183, 2008. View at Publisher · View at Google Scholar
  14. T. Toubai, Y. Sun, and P. Reddy, “GVHD pathophysiology: is acute different from chronic?” Best Practice & Research Clinical Haematology, vol. 21, no. 2, pp. 101–117, 2008. View at Google Scholar
  15. R. Korngold and J. Sprent, “Lethal graft versus host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow,” Journal of Experimental Medicine, vol. 148, no. 6, pp. 1687–1698, 1978. View at Google Scholar
  16. F. Aversa, “Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States,” Bone Marrow Transplantation, vol. 41, no. 5, pp. 473–481, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. T. Teshima, T. A. Wynn, R. J. Soiffer, K. I. Matsuoka, and P. J. Martin, “Chronic graft-versus-host disease: how can we release Prometheus?” Biology of Blood and Marrow Transplantation, vol. 14, supplement 1, pp. 142–150, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. A. Tyndall and F. Dazzi, “Chronic GVHD as an autoimmune disease,” Best Practice and Research Clinical Haematology, vol. 21, no. 2, pp. 281–289, 2008. View at Publisher · View at Google Scholar · View at PubMed
  19. L. Rozendaal, S. T. Pals, E. Gleichmann, and C. J. M. Melief, “Persistence of allospecific helper T cells is required for maintaining autoantibody formation in lupus-like graft-versus-host disease,” Clinical and Experimental Immunology, vol. 82, no. 3, pp. 527–532, 1990. View at Google Scholar
  20. N. Fukushi, H. Arase, B. Wang et al., “Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 16, pp. 6301–6305, 1990. View at Publisher · View at Google Scholar
  21. T. Ghayur, T. A. Seemayer, A. Xenocostas, and W. S. Lapp, “Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease,” American Journal of Pathology, vol. 133, no. 1, pp. 39–46, 1988. View at Google Scholar
  22. W. Krenger and G. A. Holländer, “The immunopathology of thymic GVHD,” Seminars in Immunopathology, vol. 30, no. 4, pp. 439–456, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. Y. Sakoda, D. Hashimoto, S. Asakura et al., “Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease,” Blood, vol. 109, no. 4, pp. 1756–1764, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. H. Groux, A. O'Garra, M. Bigler et al., “A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis,” Nature, vol. 389, no. 6652, pp. 737–742, 1997. View at Publisher · View at Google Scholar · View at PubMed
  25. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar · View at PubMed
  26. N. Seddiki, B. Santner-Nanan, J. Martinson et al., “Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells,” Journal of Experimental Medicine, vol. 203, no. 7, pp. 1693–1700, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. M. G. Roncarolo and M. Battaglia, “Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans,” Nature Reviews Immunology, vol. 7, no. 8, pp. 585–598, 2007. View at Publisher · View at Google Scholar · View at PubMed
  28. K. Rezvani, S. Mielke, M. Ahmadzadeh et al., “High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT,” Blood, vol. 108, no. 4, pp. 1291–1297, 2006. View at Publisher · View at Google Scholar · View at PubMed
  29. E. Zorn, H. T. Kim, S. J. Lee et al., “Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease,” Blood, vol. 106, no. 8, pp. 2903–2911, 2005. View at Publisher · View at Google Scholar · View at PubMed
  30. Y. Miura, C. J. Thoburn, E. C. Bright et al., “Association of Foxp3 regulatory gene expression with graft-versus-host disease,” Blood, vol. 104, no. 7, pp. 2187–2193, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. F. J. Clark, R. Gregg, K. Piper et al., “Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells,” Blood, vol. 103, no. 6, pp. 2410–2416, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. K. Rieger, C. Loddenkemper, J. Maul et al., “Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD,” Blood, vol. 107, no. 4, pp. 1717–1723, 2006. View at Publisher · View at Google Scholar · View at PubMed
  33. P. Trzonkowski, M. Bieniaszewska, J. Juscinska et al., “First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells,” Clinical Immunology, vol. 133, no. 1, pp. 22–26, 2009. View at Publisher · View at Google Scholar · View at PubMed
  34. A. Shimabukuro-Vornhagen, M. J. Hallek, R. F. Storb, and M. S. von Bergwelt-Baildon, “The role of B cells in the pathogenesis of graft-versus-host disease,” Blood, vol. 114, no. 24, pp. 4919–4927, 2009. View at Publisher · View at Google Scholar · View at PubMed
  35. R. Kapur, S. Ebeling, and A. Hagenbeek, “B-cell involvement in chronic graft-versus-host disease,” Haematologica, vol. 93, no. 11, pp. 1702–1711, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. E. Zorn, D. B. Miklos, B. H. Floyd et al., “Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation,” Journal of Experimental Medicine, vol. 199, no. 8, pp. 1133–1142, 2004. View at Publisher · View at Google Scholar · View at PubMed
  37. D. B. Miklos, H. T. Kim, K. H. Miller et al., “Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission,” Blood, vol. 105, no. 7, pp. 2973–2978, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. S. Svegliati, A. Olivieri, N. Campelli et al., “Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease,” Blood, vol. 110, no. 1, pp. 237–241, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Thien, T. G. Phan, S. Gardam et al., “Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches,” Immunity, vol. 20, no. 6, pp. 785–798, 2004. View at Publisher · View at Google Scholar · View at PubMed
  40. S. Sarantopoulos, K. E. Stevenson, H. T. Kim et al., “High levels of B-cell activating factor in patients with active chronic graft-versus-host disease,” Clinical Cancer Research, vol. 13, no. 20, pp. 6107–6114, 2007. View at Publisher · View at Google Scholar · View at PubMed
  41. S. Sarantopoulos, K. E. Stevenson, H. T. Kim et al., “Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease,” Blood, vol. 113, no. 16, pp. 3865–3874, 2009. View at Publisher · View at Google Scholar · View at PubMed
  42. K. She, A. L. Gilman, S. Aslanian et al., “Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 13, no. 4, pp. 386–397, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. A. Gabrielli, E. V. Avvedimento, and T. Krieg, “Scleroderma,” The New England Journal of Medicine, vol. 360, no. 19, pp. 1989–2003, 2009. View at Publisher · View at Google Scholar · View at PubMed
  44. C. Skert, F. Patriarca, A. Sperotto et al., “Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome,” Haematologica, vol. 91, no. 2, pp. 258–261, 2006. View at Google Scholar
  45. B. D. Jaffee and H. N. Claman, “Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems,” Cellular Immunology, vol. 77, no. 1, pp. 1–12, 1983. View at Google Scholar
  46. Y. DeClerck, V. Draper, and R. Parkman, “Clonal analysis of murine graft-vs-host disease. II leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs. host disease,” Journal of Immunology, vol. 136, no. 10, pp. 3549–3552, 1986. View at Google Scholar
  47. L. L. McCormick, Y. Zhang, E. Tootell, and A. C. Gilliam, “Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma,” Journal of Immunology, vol. 163, no. 10, pp. 5693–5699, 1999. View at Google Scholar
  48. Y. Zhang, L. L. McCormick, and A. C. Gilliam, “Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation,” Journal of Immunology, vol. 168, no. 6, pp. 3088–3098, 2002. View at Google Scholar
  49. Y. Zhang, L. L. McCormick, and A. C. Gilliam, “Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma,” Journal of Investigative Dermatology, vol. 121, no. 4, pp. 713–719, 2003. View at Publisher · View at Google Scholar · View at PubMed
  50. S. S. Baroni, M. Santillo, F. Bevilacqua et al., “Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis,” The New England Journal of Medicine, vol. 354, no. 25, pp. 2667–2676, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. S. Smaldone, J. Olivieri, G. L. Gusella, G. Moroncini, A. Gabrielli, and F. Ramirez, “Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts,” Fibrogenesis Tissue Repair, vol. 4, article 8, 2011. View at Publisher · View at Google Scholar · View at PubMed
  52. D. Wolff, A. Gerbitz, F. Ayuk et al., “Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD,” Biology of Blood and Marrow Transplantation, vol. 16, no. 12, pp. 1611–1628, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. G. B. Vogelsang, “How I treat chronic graft-versus-host disease,” Blood, vol. 97, no. 5, pp. 1196–1201, 2001. View at Publisher · View at Google Scholar
  54. S. Koc, W. Leisenring, M. E. D. Flowers et al., “Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone,” Blood, vol. 100, no. 1, pp. 48–51, 2002. View at Publisher · View at Google Scholar
  55. K. Baird, K. Cooke, and K. R. Schultz, “Chronic graft-versus-host disease (GVHD) in children,” Pediatric Clinics of North America, vol. 57, no. 1, pp. 297–322, 2010. View at Publisher · View at Google Scholar · View at PubMed
  56. G. Socie, J. Ritz, and P. J. Martin, “Current challenges in chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 16, supplement 1, pp. S146–S151, 2010. View at Google Scholar
  57. D. Wolff, M. Schleuning, S. von Harsdorf et al., “Consensus conference on clinical practice in chronic GVHD: second-line Treatment of chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 17, pp. 1–17, 2010. View at Publisher · View at Google Scholar · View at PubMed
  58. M. Berger, E. Biasin, F. Saglio, and F. Fagioli, “Innovative approaches to treat steroid-resistant or steroid refractory GVHD,” Bone Marrow Transplantation, vol. 42, supplement 2, pp. S101–S105, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. C. Cutler, D. Miklos, H. T. Kim et al., “Rituximab for steroid-refractory chronic graft-versus-host disease,” Blood, vol. 108, no. 2, pp. 756–762, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. A. M. Carella, S. Biasco, S. Nati, A. Congiu, and E. Lerma, “Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease,” Leukemia and Lymphoma, vol. 48, no. 3, pp. 623–624, 2007. View at Publisher · View at Google Scholar · View at PubMed
  61. M. Mohty, N. Marchetti, J. El Cheikh, C. Faucher, S. Furst, and D. Blaise, “Rituximab as salvage therapy for refractory chronic GVHD,” Bone Marrow Transplantation, vol. 41, no. 10, pp. 909–911, 2008. View at Publisher · View at Google Scholar · View at PubMed
  62. M. Okamoto, A. Okano, S. Akamatsu et al., “Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease,” Leukemia, vol. 20, no. 1, pp. 172–173, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. T. Teshima, K. Nagafuji, H. Henzan et al., “Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease,” International Journal of Hematology, vol. 90, no. 2, pp. 253–260, 2009. View at Publisher · View at Google Scholar · View at PubMed
  64. M. R. Canninga-Van Dijk, H. M. van der Straaten, R. Fijnheer, C. J. Sanders, J. G. Van Den Tweel, and L. F. Verdonck, “Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease,” Blood, vol. 104, no. 8, pp. 2603–2606, 2004. View at Publisher · View at Google Scholar · View at PubMed
  65. V. Ratanatharathorn, L. Ayash, C. Reynolds et al., “Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody,” Biology of Blood and Marrow Transplantation, vol. 9, no. 8, pp. 505–511, 2003. View at Publisher · View at Google Scholar
  66. F. Zaja, A. Bacigalupo, F. Patriarca et al., “Treatment of refractory chronic GVHD with rituximab: a GITMO study,” Bone Marrow Transplantation, vol. 40, no. 3, pp. 273–277, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. M. Von Bonin, U. Oelschlagel, J. Radke et al., “Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab,” Transplantation, vol. 86, no. 6, pp. 875–879, 2008. View at Publisher · View at Google Scholar · View at PubMed
  68. M. A. Kharfan-Dabaja, A. R. Mhaskar, B. Djulbegovic, C. Cutler, M. Mohty, and A. Kumar, “Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis,” Biology of Blood and Marrow Transplantation, vol. 15, no. 9, pp. 1005–1013, 2009. View at Publisher · View at Google Scholar · View at PubMed
  69. D. R. Couriel, C. Hosing, R. Saliba et al., “Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD,” Blood, vol. 107, no. 8, pp. 3074–3080, 2006. View at Publisher · View at Google Scholar · View at PubMed
  70. M. E. D. Flowers, J. F. Apperley, K. van Besien et al., “A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease,” Blood, vol. 112, no. 7, pp. 2667–2674, 2008. View at Publisher · View at Google Scholar · View at PubMed
  71. D. A. Jacobsohn, A. R. Chen, M. Zahurak et al., “Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease,” Journal of Clinical Oncology, vol. 25, no. 27, pp. 4255–4261, 2007. View at Publisher · View at Google Scholar · View at PubMed
  72. B. Mookerjee, V. Altomonte, and G. Vogelsang, “Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus,” Bone Marrow Transplantation, vol. 24, no. 5, pp. 517–520, 1999. View at Google Scholar
  73. F. Lopez, P. Parker, A. Nademanee et al., “Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 11, no. 4, pp. 307–313, 2005. View at Publisher · View at Google Scholar · View at PubMed
  74. A. Busca, F. Locatelli, F. Marmont, E. Audisia, and M. Falda, “Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease,” Haematologica, vol. 88, no. 7, pp. 837–839, 2003. View at Google Scholar
  75. G. Akpek, S. M. Lee, V. Anders, and G. B. Vogelsang, “A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 7, no. 9, pp. 495–502, 2001. View at Google Scholar
  76. A. Kanamaru, Y. Takemoto, E. Kakishita et al., “FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT study group,” Bone Marrow Transplantation, vol. 15, no. 6, pp. 885–889, 1995. View at Google Scholar
  77. D. R. Couriel, R. Saliba, M. P. Escalan et al., “Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease,” British Journal of Haematology, vol. 130, no. 3, pp. 409–417, 2005. View at Publisher · View at Google Scholar · View at PubMed
  78. L. J. Johnston, J. Brown, J. A. Shizuru et al., “Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 11, no. 1, pp. 47–55, 2005. View at Publisher · View at Google Scholar · View at PubMed
  79. H. T. Greinix, B. Volc-Platzer, P. Kalhs et al., “Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study,” Blood, vol. 96, no. 7, pp. 2426–2431, 2000. View at Google Scholar
  80. E. Buchdunger, C. L. Cioffi, N. Law et al., “Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 139–145, 2000. View at Google Scholar
  81. M. C. Heinrich, C. L. Corless, A. Duensing et al., “PDGFRA activating mutations in gastrointestinal stromal tumors,” Science, vol. 299, no. 5607, pp. 708–710, 2003. View at Publisher · View at Google Scholar · View at PubMed
  82. G. D. Demetri, M. von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” The New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at PubMed
  83. T. Hunter, “Treatment for chronic myelogenous leukemia: the long road to imatinib,” Journal of Clinical Investigation, vol. 117, no. 8, pp. 2036–2043, 2007. View at Publisher · View at Google Scholar · View at PubMed
  84. C. Ustun, D. L. Deremer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” Leukemia Research, vol. 35, no. 9, pp. 1143–1152, 2011. View at Google Scholar
  85. B. J. Druker, F. Guilhot, S. G. O'Brien et al., “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2408–2417, 2006. View at Publisher · View at Google Scholar · View at PubMed
  86. A. Hochhaus, B. Druker, C. Sawyers et al., “Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment,” Blood, vol. 111, no. 3, pp. 1039–1043, 2008. View at Publisher · View at Google Scholar · View at PubMed
  87. M. H. Cohen, J. R. Johnson, and R. Pazdur, “U.S. food and drug administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval,” Clinical Cancer Research, vol. 11, no. 1, pp. 12–19, 2005. View at Google Scholar
  88. R. Kerkela, L. Grazette, R. Yacobi et al., “Cardiotoxicity of the cancer therapeutic agent imatinib mesylate,” Nature Medicine, vol. 12, no. 8, pp. 908–916, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. C. Gambacorti, L. Tornaghi, A. Franceschino, R. Piazza, G. Corneo, and E. Pogliani, “In reply to ‘cardiotoxicity of the cancer therapeutic agent imatinib mesylate’,” Nature Medicine, vol. 13, no. 1, pp. 13–14, 2007. View at Publisher · View at Google Scholar · View at PubMed
  90. A. Hatfield, S. Owen, and P. R. Pilot, “In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate',” Nature Medicine, vol. 13, no. 1, pp. 13–16, 2007. View at Publisher · View at Google Scholar · View at PubMed
  91. E. Atallah, J. B. Durand, H. Kantarjian, and J. Cortes, “Congestive heart failure is a rare event in patients receiving imatinib therapy,” Blood, vol. 110, no. 4, pp. 1233–1237, 2007. View at Publisher · View at Google Scholar · View at PubMed
  92. M. J. Burke, B. Trotz, X. Luo et al., “Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients,” Bone Marrow Transplantation, vol. 44, no. 3, pp. 169–174, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. F. J. Giles, M. O'Dwyer, and R. Swords, “Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia,” Leukemia, vol. 23, no. 10, pp. 1698–1707, 2009. View at Publisher · View at Google Scholar · View at PubMed
  94. H. Kantarjian, F. Giles, L. Wunderle et al., “Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL,” The New England Journal of Medicine, vol. 354, no. 24, pp. 2542–2551, 2006. View at Publisher · View at Google Scholar · View at PubMed
  95. P. Anderlini, S. Sheth, K. Hicks, C. Ippoliti, S. Giralt, and R. E. Champlin, “Re: imatinib mesylate administration in the first 100 days after stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 10, no. 12, pp. 883–884, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. P. A. Carpenter, D. S. Snyder, M. E. D. Flowers et al., “Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia,” Blood, vol. 109, no. 7, pp. 2791–2793, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. A. Olivieri and L. Manzione, “Dasatinib: a new step in molecular target therapy,” Annals of Oncology, vol. 18, supplement 6, pp. 542–546, 2007. View at Publisher · View at Google Scholar · View at PubMed
  98. O. Ottmann, H. Dombret, G. Martinelli et al., “Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study,” Blood, vol. 110, no. 7, pp. 2309–2315, 2007. View at Publisher · View at Google Scholar · View at PubMed
  99. H. J. Khoury, F. Guilhot, T. P. Hughes, D. W. Kim, and J. E. Cortes, “Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations,” Cancer, vol. 115, no. 7, pp. 1381–1394, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. E. Weisberg, P. W. Manley, W. Breitenstein et al., “Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl,” Cancer Cell, vol. 7, no. 2, pp. 129–141, 2005. View at Publisher · View at Google Scholar · View at PubMed
  101. S. Merante, A. A. Colombo, S. Calatroni et al., “Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation,” Bone Marrow Transplantation, vol. 44, no. 4, pp. 263–264, 2009. View at Publisher · View at Google Scholar · View at PubMed
  102. F. Boschelli, K. Arndt, and C. Gambacorti-Passerini, “Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia,” European Journal of Cancer, vol. 46, no. 10, pp. 1781–1789, 2010. View at Publisher · View at Google Scholar · View at PubMed
  103. P. A. Zipfel, W. Zhang, M. Quiroz, and A. M. Pendergast, “Requirement for Abl kinases in T cell receptor signaling,” Current Biology, vol. 14, no. 14, pp. 1222–1231, 2004. View at Publisher · View at Google Scholar · View at PubMed
  104. P. A. Zipfel, M. Grove, K. Blackburn, M. Fujimoto, T. F. Tedder, and A. M. Pendergast, “The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19,” Journal of Immunology, vol. 165, no. 12, pp. 6872–6879, 2000. View at Google Scholar
  105. V. L. J. Tybulewicz, C. E. Crawford, P. K. Jackson, R. T. Bronson, and R. C. Mulligan, “Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene,” Cell, vol. 65, no. 7, pp. 1153–1163, 1991. View at Google Scholar
  106. V. Agosti, S. Corbacioglu, I. Ehlers et al., “Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development,” Journal of Experimental Medicine, vol. 199, no. 6, pp. 867–878, 2004. View at Publisher · View at Google Scholar · View at PubMed
  107. K. Miyachi, A. Ihara, R. W. Hankins, R. Murai, S. Maehiro, and H. Miyashita, “Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia,” Clinical Rheumatology, vol. 22, no. 4-5, pp. 329–332, 2003. View at Publisher · View at Google Scholar · View at PubMed
  108. K. K. Eklund and H. Joensuu, “Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases,” Annals of Medicine, vol. 35, no. 5, pp. 362–367, 2003. View at Publisher · View at Google Scholar
  109. A. Olivieri, M. Cimminiello, F. Locatelli et al., “Imatinib is safe and effective in patients with refractory Chronic Graft Versus Host Disease: analysis of two consecutive prospective GITMO studies,” Blood, vol. 116, article 246, 2010. View at Google Scholar
  110. R. T. Paniagua, O. Sharpe, P. P. Ho et al., “Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis,” Journal of Clinical Investigation, vol. 116, no. 10, pp. 2633–2642, 2006. View at Publisher · View at Google Scholar · View at PubMed
  111. A. B. Dietz, L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, and S. Vuk-Pavlović, “Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo,” Blood, vol. 104, no. 4, pp. 1094–1099, 2004. View at Publisher · View at Google Scholar · View at PubMed
  112. R. Seggewiss, K. Lore, E. Greiner et al., “Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner,” Blood, vol. 105, no. 6, pp. 2473–2479, 2005. View at Publisher · View at Google Scholar · View at PubMed
  113. S. Ho, N. Clipstone, L. Timmermann et al., “The mechanism of action of cyclosporin A and FK506,” Clinical Immunology and Immunopathology, vol. 80, no. 3, pp. S40–S45, 1996. View at Publisher · View at Google Scholar
  114. R. Seggewiss, D. A. Price, and M. A. Purbhoo, “Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update,” Cytotherapy, vol. 10, no. 6, pp. 633–641, 2008. View at Publisher · View at Google Scholar · View at PubMed
  115. K. Cwynarksi, R. Laylor, E. Macchiarulo et al., “Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro,” Leukemia, vol. 18, no. 8, pp. 1332–1339, 2004. View at Publisher · View at Google Scholar · View at PubMed
  116. R. Zamoyska, A. Basson, A. Filby, G. Legname, M. Lovatt, and B. Seddon, “The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation,” Immunological Reviews, vol. 191, pp. 107–118, 2003. View at Publisher · View at Google Scholar
  117. A. E. Schade, G. L. Schieven, R. Townsend et al., “Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation,” Blood, vol. 111, no. 3, pp. 1366–1377, 2008. View at Publisher · View at Google Scholar · View at PubMed
  118. J. Das, P. Chen, D. Norris et al., “2-aminothiazole as a novel kinase inhibitor template Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor,” Journal of Medicinal Chemistry, vol. 49, no. 23, pp. 6819–6832, 2006. View at Publisher · View at Google Scholar · View at PubMed
  119. R. Weichsel, C. Dix, L. Wooldridge et al., “Profound inhibition of antigen-specific T-cell effector functions by dasatinib,” Clinical Cancer Research, vol. 14, no. 8, pp. 2484–2491, 2008. View at Publisher · View at Google Scholar · View at PubMed
  120. N. Larmonier, N. Janikashvili, C. J. Lacasse et al., “Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors,” Journal of Immunology, vol. 181, no. 10, pp. 6955–6963, 2008. View at Google Scholar
  121. E. Buchdunger, A. Matter, and B. J. Druker, “Bcr-Abl inhibition as a modality of CML therapeutics,” Biochimica et Biophysica Acta, vol. 1551, pp. M11–M18, 2001. View at Google Scholar
  122. M. A. Fabian, W. H. Biggs III, D. K. Treiber et al., “A small molecule-kinase interaction map for clinical kinase inhibitors,” Nature Biotechnology, vol. 23, no. 3, pp. 329–336, 2005. View at Publisher · View at Google Scholar · View at PubMed
  123. R. Santachiara, R. Maffei, S. Martinelli et al., “Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor,” Haematologica, vol. 93, no. 8, pp. 1252–1255, 2008. View at Publisher · View at Google Scholar · View at PubMed
  124. J. L. Steegmann, G. Moreno, C. Aláez et al., “Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia,” Haematologica, vol. 88, no. 7, pp. 762–768, 2003. View at Google Scholar
  125. G. Napolitani, N. Bortoletto, L. Racioppi, A. Lanzavecchia, and U. D'Oro, “Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation,” European Journal of Immunology, vol. 33, no. 10, pp. 2832–2841, 2003. View at Publisher · View at Google Scholar · View at PubMed
  126. C. L. Chu and C. A. Lowell, “The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation,” Journal of Immunology, vol. 175, no. 5, pp. 2880–2889, 2005. View at Google Scholar
  127. S. Appel, A. M. Boehmler, F. Grünebach et al., “Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells,” Blood, vol. 103, no. 2, pp. 538–544, 2004. View at Publisher · View at Google Scholar · View at PubMed
  128. S. Appel, A. Rupf, M. M. Weck et al., “Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways,” Clinical Cancer Research, vol. 11, no. 5, pp. 1928–1940, 2005. View at Publisher · View at Google Scholar · View at PubMed
  129. H. Wang, F. Cheng, A. Cuenca et al., “Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance,” Blood, vol. 105, no. 3, pp. 1135–1143, 2005. View at Publisher · View at Google Scholar · View at PubMed
  130. C. Borg, M. Terme, J. Taïeb et al., “Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects,” Journal of Clinical Investigation, vol. 114, no. 3, pp. 379–388, 2004. View at Publisher · View at Google Scholar
  131. J. Taieb, N. Chaput, C. Ménard et al., “A novel dendritic cell subset involved in tumor immunosurveillance,” Nature Medicine, vol. 12, no. 2, pp. 214–219, 2006. View at Publisher · View at Google Scholar · View at PubMed
  132. G. W. Chan, G. Gorgun, K. B. Miller, and F. M. Foss, “Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 9, no. 3, pp. 170–176, 2003. View at Google Scholar
  133. M. Deininger, E. Buchdunger, and B. J. Druker, “The development of imatinib as a therapeutic agent for chronic myeloid leukemia,” Blood, vol. 105, no. 7, pp. 2640–2653, 2005. View at Publisher · View at Google Scholar · View at PubMed
  134. C. Louvet, G. L. Szot, J. Lang et al., “Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 48, pp. 18895–18900, 2008. View at Publisher · View at Google Scholar · View at PubMed
  135. L. K. M. Shoda, D. L. Young, S. Ramanujan et al., “A comprehensive review of interventions in the NOD mouse and implications for translation,” Immunity, vol. 23, no. 2, pp. 115–126, 2005. View at Publisher · View at Google Scholar · View at PubMed
  136. Y. Aono, Y. Nishioka, M. Inayama et al., “Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 11, pp. 1279–1285, 2005. View at Publisher · View at Google Scholar · View at PubMed
  137. J. H. W. Distler, A. Jüngel, L. C. Huber et al., “Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 311–322, 2007. View at Publisher · View at Google Scholar · View at PubMed
  138. A. Akhmetshina, C. Dees, M. Pileckyte et al., “Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis,” FASEB Journal, vol. 22, no. 7, pp. 2214–2222, 2008. View at Publisher · View at Google Scholar · View at PubMed
  139. A. V. Kamath, J. Wang, F. Y. Lee, and P. H. Marathe, “Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL,” Cancer Chemotherapy and Pharmacology, vol. 61, pp. 365–376, 2008. View at Google Scholar
  140. P. Kaur, N. Feldhahn, B. Zhang et al., “Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia,” Molecular Cancer, vol. 6, article 67, 2007. View at Publisher · View at Google Scholar · View at PubMed
  141. F. R. Luo, Z. Yang, A. Camuso et al., “Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure,” Clinical Cancer Research, vol. 12, no. 23, pp. 7180–7186, 2006. View at Publisher · View at Google Scholar · View at PubMed
  142. C. E. Daniels, M. C. Wikes, M. Edens et al., “Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin mediated lung fibrosis,” Journal of Clinical Investigation, vol. 114, pp. 1308–1316, 2004. View at Google Scholar
  143. S. Wang, M. C. Wilkes, E. B. Leof, and R. Hirschberg, “Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo,” FASEB Journal, vol. 19, no. 1, pp. 1–11, 2005. View at Publisher · View at Google Scholar · View at PubMed
  144. H. Yoshiji, R. Noguchi, S. Kuriyama et al., “Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats,” AJP—Gastrointestinal and Liver Physiology, vol. 288, pp. G907–G913, 2005. View at Google Scholar
  145. C. Leipner, K. Grün, A. Müller et al., “Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis,” Cardiovascular Research, vol. 79, no. 1, pp. 118–126, 2008. View at Publisher · View at Google Scholar · View at PubMed
  146. J. Gordon and R. Spiera, “Imatinib and the treatment of fibrosis: recent trials and tribulations,” Current Rheumatology Reports, vol. 13, pp. 51–58, 2011. View at Google Scholar
  147. J. Kay and W. A. High, “Imatinib mesylate treatment of nephrogenic systemic fibrosis,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2543–2548, 2008. View at Publisher · View at Google Scholar · View at PubMed
  148. R. F. Spiera, J. K. Gordon, J. N. Mersten et al., “Imatinib mesylate (gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial,” Annals of the Rheumatic Diseases, vol. 70, pp. 1003–1009, 2011. View at Google Scholar
  149. C. E. Daniels, J. A. Lasky, A. H. Limper, K. Mieras, E. Gabor, and D. R. Schroeder, “Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results,” American Journal of Respiratory and Critical Care Medicine, vol. 181, pp. 604–610, 2010. View at Google Scholar
  150. Y. Shi and J. Massagué, “Mechanisms of TGF-beta signaling from cell membrane to the nucleus,” Cell, vol. 113, no. 6, pp. 685–700, 2003. View at Publisher · View at Google Scholar
  151. M. Trojanowska, “Noncanonical transforming growth factor beta signaling in scleroderma fibrosis,” Current Opinion in Rheumatology, vol. 21, no. 6, pp. 623–629, 2009. View at Publisher · View at Google Scholar · View at PubMed
  152. N. Iwamoto, J. H. Distler, and O. Distler, “Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials,” Current Rheumatology Reports, vol. 13, pp. 21–27, 2011. View at Google Scholar
  153. A. M. Pendergast, “The Abl family kinases: mechanisms of regulation and signaling,” Advances in Cancer Research, vol. 85, pp. 51–100, 2002. View at Publisher · View at Google Scholar
  154. S. Bhattacharyya, W. Ishida, M. Wu et al., “A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate,” Oncogene, vol. 28, no. 10, pp. 1285–1297, 2009. View at Publisher · View at Google Scholar · View at PubMed
  155. J. Pannu, Y. Asano, S. Nakerakanti et al., “Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2528–2537, 2008. View at Publisher · View at Google Scholar · View at PubMed
  156. S. S. Nakerakanti, A. M. Bujor, and M. Trojanowska, “CCN2 is required for the TGF-β induced activation of Smad1 - Erk1/2 signaling network,” PLoS One, vol. 6, Article ID e21911, 2011. View at Google Scholar
  157. A. M. Bujor, Y. Asano, P. Haines, R. Lafyatis, and M. Trojanowska, “The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts,” Arthritis & Rheumatism, vol. 63, pp. 1729–1737, 2011. View at Google Scholar
  158. B. Maurer, J. Stanczyk, A. Jüngel et al., “MicroRNA-29, a key regulator of collagen expression in systemic sclerosis,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1733–1743, 2010. View at Publisher · View at Google Scholar · View at PubMed
  159. M. Deininger, M. Schleuning, H. Greinix et al., “The effect of prior exposure to imatinib on transplant-related mortality,” Haematologica, vol. 91, pp. 452–459, 2006. View at Google Scholar
  160. S. A. Giralt, M. Arora, J. M. Goldman et al., “Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia,” British Journal of Haematology, vol. 137, pp. 461–467, 2007. View at Google Scholar
  161. V. G. Oehler, T. Gooley, D. S. Snyder et al., “The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia,” Blood, vol. 109, no. 4, pp. 1782–1789, 2007. View at Publisher · View at Google Scholar · View at PubMed
  162. N. S. Majhail, C. A. Schiffer, and D. J. Weisdorf, “Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 12, no. 7, pp. 789–791, 2006. View at Publisher · View at Google Scholar · View at PubMed
  163. L. Magro, B. Catteau, V. Coiteux, B. Bruno, J. P. Jouet, and I. Yakoub-Agha, “Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD,” Bone Marrow Transplantation, vol. 42, no. 11, pp. 757–760, 2008. View at Publisher · View at Google Scholar · View at PubMed
  164. A. Olivieri, F. Locatelli, M. Zecca et al., “Imatinib for refractory chronic graft-versus-host disease with fibrotic features,” Blood, vol. 114, no. 3, pp. 709–718, 2009. View at Publisher · View at Google Scholar · View at PubMed
  165. L. Magro, M. Mohty, B. Catteau et al., “Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease,” Blood, vol. 114, no. 3, pp. 719–722, 2009. View at Publisher · View at Google Scholar · View at PubMed
  166. M. Stadler, R. Ahlborn, H. Kamal et al., “Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease,” Blood, vol. 114, pp. 3718–3720, 2009. View at Google Scholar
  167. G. Rosti, F. Palandri, F. Castagnetti et al., “Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia,” Blood, vol. 114, pp. 4933–4338, 2009. View at Google Scholar
  168. C. J. Fraser and K. S. Baker, “The management and outcome of chronic graft-versus-host disease,” British Journal of Haematology, vol. 138, no. 2, pp. 131–145, 2007. View at Publisher · View at Google Scholar · View at PubMed